Veena Somayaji

A Long-Acting FGF21 Molecule, PF-05231023, Decreases Body Weight and Improves Lipid Profile in Non-human Primates and Type 2 Diabetic Subjects

Saswata Talukdar, Yingjiang Zhou, Dongmei Li et al. · Cell Metabolism · 2016 · 477 citations · Full text

Obesity, Metabolic Syndrome, Long-acting Fgf21 Molecule +12

ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials

Roberto A. Calle, Neeta B. Amin, Santos Carvajal‐Gonzalez et al. · Nature Medicine · 2021 · 207 citations

Obesity, Metabolic Syndrome, Dgat2 Inhibitor +12

Once‐weekly administration of a long‐acting fibroblast growth factor 21 analogue modulates lipids, bone turnover markers, blood pressure and body weight differently in obese people with hypertriglyceridaemia and in non‐human primates

Albert M. Kim, Veena Somayaji, Jennifer Dong et al. · Diabetes Obesity and Metabolism · 2017 · 136 citations

Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene

Michael R. McClung, Ethel S. Siris, Steve Cummings et al. · Menopause The Journal of The North American Menopause Society · 2006 · 109 citations

Pharmacokinetics and pharmacodynamics of PF‐05231023, a novel long‐acting FGF21 mimetic, in a first‐in‐human study

Jennifer Dong, Michelle I. Rossulek, Veena Somayaji et al. · British Journal of Clinical Pharmacology · 2015 · 98 citations · Full text